Disease Education Resources
Oncology
Explore our library of Lilly-created medical education resources.
Breast Cancer - Metastatic
VIDEO: A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC
In this video, renowned oncologist Dr. Joyce O’Shaughnessy speaks about how treatment outcomes may vary for patients with HR+, HER2- MBC depending on the breast cancer subtype and the underlying disease heterogeneity.
VIDEO: CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC
In this video, Dr. Joyce O’Shaughnessy shares her expertise on the standard of care first-line treatment for patients with HR+, HER2- MBC and the efficacy and safety data for CDK4/6 inhibitors in this setting.
VIDEO: Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and Sequencing
In this video, Dr. Joyce O’Shaughnessy discusses the treatment landscape for patients who progress on ET + CDK4/6 inhibitors, including the importance of biomarker testing in this setting.
VIDEO: Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- MBC
In this video, renowned oncologist Dr. Komal Jhaveri discusses mechanisms of endocrine resistance, including an overview of ESR1 mutations and recommendations for testing.
VIDEO: SERDS: Relevance and Role in Current & Future Treatments for HR+, HER2- MBC
In this video, Dr. Komal Jhaveri shares her expertise on SERDs for the treatment of HR+, HER2- MBC, including the evolving role of novel oral SERDs.
This slide deck aims to provide an overview of metastatic breast cancer, including subtypes and prognoses, and a summary of systemic and targeted treatments. Learn more.
This slide deck provides an overview of non-endocrine, targeted treatment options in HR+, HER2- MBC, including information on the MOA of different therapy classes and the phase 2/3 clinical studies for approved therapies in this setting.
This slide deck provides an overview of the ER+, HER2- advanced breast cancer landscape, including information on ER targeted therapies, mechanisms of resistance to ET +/- CDK4/6 inhibitors, & scientific advancements in the form of next-generation ETs.
This infographic is intended to educate healthcare providers on the heterogeneity of HR+, HER2- metastatic breast cancer, factors more likely to confer a poorer prognosis, and information on the standard first-line treatment for patients.
This infographic is intended to educate healthcare providers on the unmet need for patients who progress on 1L standard of care for HR+, HER2- metastatic breast cancer, and includes clinical research to support treatment decisions in the 2L setting.
This infographic introduces ER+, HER2-, ABC, how the estrogen pathway is being targeted by 3 classes of endocrine therapies (ET), and the unmet needs that remain
This infographic provides an overview of resistance mechanisms against ET; highlighting ESR1 mutations, including when and how to test for these mutations in ER+, HER2-, ABC
This infographic summarizes the complex treatment landscape after progression or recurrence on ET+ CKD4/6 inhibitors in ER+, HER2-, ABC and the limitations for the 3 main classes of approved ETs
This infographic provides an overview of the approved and investigational ET classes in ER+, HER2-, ABC; highlights the potential benefits of next-generation ETs, resulting in more potent endocrine pathway antagonism
Patient Education Resources
Explore our library of patient based education materials to aid in HCP to patient interactions.